SCHEMBL29389253

SCHEMBL29389253

CCn1c2ccccc2c2cc(/C=C/c3ccc4ccccc4[n+]3C)ccc21

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 14/20 0.98
▸ BCHE P06276 5/20 0.98
▸ POLB P06746 5/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ PKM P14618 2/20 0.53
▸ HTT P42858 2/20 0.53
▸ KMT2A Q03164 4/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ MAPT P10636 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ SRC P12931 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20380843 1.00 ACHE (0.98) ACHEBCHEPOLBKDM4EPKM
SCHEMBL16183136 0.87 ACHE (0.76) ACHEBCHEPOLBKDM4EPKM
SCHEMBL3443606 0.80 KDM4E (0.68) ACHEBCHEPOLBKDM4EPKM
SCHEMBL29415213 0.80 KDM4E (0.68) ACHEBCHEPOLBKDM4EPKM
SCHEMBL85408 0.80 KDM4E (0.68) ACHEBCHEPOLBKDM4EPKM
SCHEMBL29357702 0.80 KDM4E (0.68) ACHEBCHEPOLBKDM4EPKM
SCHEMBL10013256 0.79 KDM4E (0.67) ACHEBCHEPOLBKDM4EPKM
SCHEMBL20380420 0.78 BCHE (0.62) ACHEBCHEPOLBKDM4EPKM
SCHEMBL16183139 0.78 BCHE (0.62) ACHEBCHEPOLBKDM4EPKM
SCHEMBL133177 0.77 KDM4E (0.65) ACHEBCHEPOLBKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326850-A1 TREATMENT OF LUPUS ASTRAZENECA AB (SE) 2025-10-23 — — US disclosed
EP-4603508-A2 ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE Surrozen Operating, Inc. (US) 2025-08-20 — — EP disclosed
US-12241090-B2 Methods and systems for converting precursor cells into gastric tissues through directed differentiation CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-03-04 — — US disclosed
CN-119013289-A Modified IL-18 polypeptides 明峰治疗股份公司 2024-11-22 — — CN disclosed
US-20240368287-A1 ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE Surrozen Operating, Inc. 2024-11-07 — — US disclosed
US-12006368-B2 Anti-frizzled antibodies and methods of use Surrozen Operating, Inc. (US) 2024-06-11 — — US disclosed
EP-4377349-A1 TREATMENT OF LUPUS Astrazeneca AB (SE) 2024-06-05 — — EP disclosed
US-20240141055-A1 Human Anti-CD27 Antibodies JANSSEN BIOTECH INC (US) 2024-05-02 — — US disclosed
CN-117946267-A Anti-frizzled antibodies and methods of use 瑟罗泽恩奥普瑞汀公司 2024-04-30 — — CN disclosed
CN-111655729-B Anti-Frizzled Antibodies and Methods of Use 瑟罗泽恩奥普瑞汀公司 2023-10-20 — — CN disclosed
US-11732050-B2 Neutralizing human anti-CD27 antibodies JANSSEN BIOTECH, INC. (US) 2023-08-22 — — US disclosed
WO-2023006700-A1 TREATMENT OF LUPUS ASTRAZENECA AB (SE) 2023-02-02 — — WO disclosed
WO-2023277763-A1 METHOD OF PREPARING DNA FROM FORMALIN-FIXED-PARAFFIN-EMBEDDED (FFPE) TISSUE SAMPLES CHEN XINGQI (SE) 2023-01-05 — — WO disclosed
US-20220056420-A1 METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO GASTRIC TISSUES THROUGH DIRECTED DIFFERENTIATION CHILDREN'S HOSPITAL MEDICAL CENTER 2022-02-24 — — US disclosed
Send feedback